Clayton Trier - 13 Dec 2023 Form 4 Insider Report for U S PHYSICAL THERAPY INC /NV (USPH)

Role: Director
Signature: /s/ Clayton Trier
Issuer symbol: USPH
Transactions as of: 13 Dec 2023
Net transactions value: -$107,944
Form type: 4
Filing time: 14 Dec 2023, 17:09:39 UTC
Previous filing: 08 Dec 2023
Next filing: 14 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	USPH	Common Stock	Sale	$107,944	-1,170	-14%	$92.26	7,400	13 Dec 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.11 to $92.79, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2	Includes 800 shares of restricted stock granted under the Company equity plans. Restrictions lapse as to 400 shares on each of January 1, 2024 and April 1, 2024, subject to the grantee's continued service as a director of the Company on those dates.

Content

The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.11 to $92.79, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Includes 800 shares of restricted stock granted under the Company equity plans. Restrictions lapse as to 400 shares on each of January 1, 2024 and April 1, 2024, subject to the grantee's continued service as a director of the Company on those dates.